NATROBA (spinosad) by Cipher Pharmaceuticals is insects. Approved for pediculosis. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
NATROBA (spinosad) is a topical suspension pediculicide approved in 2011 for treating pediculosis (head lice) and scabies. It works by causing hyperexcitation followed by paralysis and death in lice and mites. Spinosad is derived from soil-dwelling bacteria and represents a distinct mechanism from older pyrethroid alternatives.
Product is in peak commercial stage with minimal Part D volume, indicating a niche market with limited growth headroom and likely small dedicated team.
insects. After periods of hyperexcitation, lice and mites become paralyzed and die.
Pediculicide
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis
Worked on NATROBA at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NATROBA offers limited career upside due to minimal market volume ($131K Part D spending) and niche positioning. Roles are predominantly field-based sales focused on dermatology or primary care channels with modest commission potential.
1 open roles linked to this drug